🔗 Share this article

This year's Nobel Prize in Physiology or Medicine was granted for transformative findings that clarify how the body's defense network targets harmful infections while sparing the body's own cells.

A trio of renowned scientists—from Japan Prof. Sakaguchi and American experts Mary Brunkow and Dr. Ramsdell—received this accolade.

The work uncovered specialized "sentinels" within the immune system that remove rogue defense cells that could harming the organism.

The findings are now enabling new therapies for immune disorders and malignancies.

These winners will share a monetary award worth 11 million Swedish kronor.

Crucial Findings

"The work has been essential for understanding how the body's defenses functions and why we don't all develop severe autoimmune diseases," stated the head of the Nobel Committee.

This team's studies explain a fundamental question: How does the defense system protect us from countless infections while leaving our own tissues intact?

Our body's protection system employs immune cells that search for signs of infection, even viruses and germs it has never encountered.

These cells utilize detectors—called receptors—that are generated randomly in a vast number of combinations.

That gives the defense network the capacity to fight a broad range of invaders, but the randomness of the process inevitably produces immune cells that can target the host.

Security Guards of the Immune System

Researchers previously understood that some of these harmful defense cells were eliminated in the immune organ—the site where white blood cells develop.

This year's Nobel Prize recognizes the identification of T-reg cells—known as the immune system's "security guards"—which patrol the body to neutralize any immune cells that attack the healthy cells.

We know that this process fails in autoimmune diseases such as juvenile diabetes, MS, and rheumatoid arthritis.

A prize committee added, "These findings have established a new field of research and spurred the creation of new therapies, for instance for tumors and autoimmune diseases."

Regarding malignancies, regulatory T-cells block the system from fighting the tumor, so research are aimed at lowering their quantity.

For autoimmune diseases, trials are exploring increasing regulatory T-cells so the body is not being harmed. A similar method could also be useful in minimizing the chances of organ transplant failure.

Innovative Studies

Prof Shimon Sakaguchi, from a Japanese institution, conducted tests on rodents that had their immune gland removed, causing autoimmune disease.

The researcher showed that injecting immune cells from healthy animals could stop the illness—suggesting there was a mechanism for preventing defenders from harming the body.

Mary Brunkow, affiliated with the a research center in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were investigating an inherited autoimmune disease in mice and people that resulted in the identification of a genetic factor vital for the way T-regs function.

"The groundbreaking research has revealed how the immune system is controlled by regulatory T cells, preventing it from accidentally targeting the body's own tissues," said a leading biological science expert.

"The research is a striking illustration of how fundamental biological research can have far-reaching implications for human health."